Surgery for ulcerative colitis in the era of biological agents therapy
10.3760/cma.j.issn.1673-9752.2016.12.018
- VernacularTitle:生物制剂时代溃疡性结肠炎的手术治疗
- Author:
Chunshan ZHAO
;
Xiaocang CAO
;
Bangmao WANG
- Keywords:
Ulcerative colitis;
Total proctocolectomy with ileal pouch-anal anastomosis;
Operating times;
Infliximab
- From:
Chinese Journal of Digestive Surgery
2016;15(12):1226-1230
- CountryChina
- Language:Chinese
-
Abstract:
Ulcerative colitis is an inflammatory disease of colon and rectum whose etiology is still unclear.Infliximab is an anti-tumor necrosis factor antibody,which has been approved recently by the United States FDA for the treatment of ulcerative colitis to reduce signs and symptoms,to induce clinical remission and healing of the intestinal mucosa.Total proctocolectomy with pouch-anal anastomosis are the standard operation for ulcerative colitis now.The perioperative infliximab use,operation timing and procedures are the important factors affecting prognosis of patients in the era of infliximab therapy.
